| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:2592.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
From the Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan (T.A., K.T., H.O., M.H.); the Department of Physiology, Tokyo Medical and Dental University, Tokyo, Japan (Y.F., Y.K.); and Ishimaru Pediatric Clinic, Matsuyama, Japan (S.N.).
Correspondence to Minoru Horie, MD, PhD, Division of Cardiac Electrophysiology, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin, Kawahara Sakyo, Kyoto, Japan 606-8507. E-mail horie{at}kuhp.kyoto-u.ac.jp
| Abstract |
|---|
|
|
|---|
Methods and Results In 3 Japanese family members with periodic paralysis, ventricular arrhythmias, and marked QT prolongation, polymerase chain reaction/single-strand conformation polymorphism/DNA sequencing identified a novel, heterozygous, missense mutation in KCNJ2, Thr192Ala (T192A), which was located in the putative cytoplasmic chain after the second transmembrane region M2. Using the Xenopus oocyte expression system, we found that the T192A mutant was nonfunctional in the homomeric condition. Coinjection with the wild-type gene reduced the current amplitude, showing a weak dominant-negative effect.
Conclusions T192, which is located in the phosphatidylinositol-4,5-bisphosphate binding site and also the region necessary for Kir2.1 multimerization, is a highly conserved amino acid residue among inward-rectifier channels. We suggest that the T192A mutation resulted in the observed electrical phenotype.
Key Words: arrhythmia paralysis ion channels genes
| Introduction |
|---|
|
|
|---|
The structure and electrophysiological properties of a cDNA-encoding mouse IRK1 (Kir2.1) have been reported.8 The human inward rectifier K+ channel is a homologue of mouse IRK1 and is expressed in the heart, skeletal muscle, and brain.9 We report a novel missense mutation of KCNJ2, T192A, in a Japanese family manifesting periodic paralysis and cardiac dysrhythmia. Its electrophysiological properties were examined in the Xenopus oocyte expression system using the 2-electrode voltage-clamp method.
| Methods |
|---|
|
|
|---|
|
The boy was born after a normal pregnancy and delivery. His developmental milestones were normal. He had afebrile seizures at 3 years; subsequently, he suffered 2 to 3 episodes a year of muscle weakness. They were of varying severity and lasted up to a few days; there were no precipitating factors. His serum potassium level was within normal limits during the paralytic attacks. At 12 years, he began to have weekly attacks, and oral acetazolamide was started. His baseline ECG showed QT prolongation (680 ms) and premature ventricular contraction bigeminy (Figure 1A). A 24-hour ambulatory ECG documented frequent premature ventricular contractions (>10 000 beats/day). He experienced no palpitations or syncope. Electromyograms revealed myogenic patterns but no myotonic discharges. Nerve conduction was normal. Muscle biopsy specimens examined by electron microscopy contained tubular aggregates.
His sister first experienced episodes of muscle weakness at 10 years. They lasted for several days and occurred without precipitating triggers. Oral acetazolamide was started. Her 12-lead ECG showed marked QT prolongation (610 ms; Figure 1A); a 24-hour ambulatory ECG documented frequent premature ventricular contractions (>10 000 beats/day) and unsustained ventricular tachycardia. She experienced no palpitations or syncope. Serum potassium levels were within normal limits during the episodes of muscle weakness.
DNA Isolation and Mutation Analysis
The protocol for genetic analysis was approved by the institutional ethics committee and performed under its guidelines. All subjects gave informed consent before gene analysis.
Genomic DNA was isolated from leukocyte nuclei by conventional methods.10 Screening for mutations of KCNJ2, KCNQ1, HERG, and SCN5A was performed by polymerase chain reaction/single-strand conformation polymorphism (PCR-SSCP) analysis.11 PCR products were heat-denatured with formamide and applied to a 13% polyacrylamide gel stained with SYBR Green II (Molecular Probes). Sequencing was on ABI sequencers (PRISM 310, PE Applied Biosystems).
In Vitro Mutagenesis
Human Kir2.1 cDNA was subcloned into pGEMHE, a high-expression vector for oocytes. The point mutant was made using a Quick Change Kit (Stratagene). The introduction of a mutation was confirmed by sequencing the mutation primer and the surrounding regions. cRNA was prepared from linearized plasmid DNA using an RNA transcription kit (Stratagene).
Voltage-Clamp Experiments
These were performed as described previously.12 Briefly, Xenopus oocytes, treated with collagenase (2 mg/mL, type 1, Sigma), were injected with
50 nL of cRNA solution and incubated at 17°C for 2 to 3 days in frog Ringer solution supplemented with 20 mmol/L KCl. The macroscopic current was recorded under a 2-electrode voltage clamp using an OC-725C amplifier (Warner) and a Digidata 1200A digitizer running pCLAMP software (Axon Instruments). The resistance of the microelectrodes, which were filled with 3 mol/L K acetate containing 10 mmol/L KCl (pH 7.2), ranged from 0.1 to 0.4 MOhm. The bath solution contained 10 mmol/L KCl, 80 mmol/L N-methylglucamine, 70 mmol/L HCl, 3 mmol/L MgCl2, and 10 mmol/L HEPES (pH 7.4). All recordings were at room temperature (23±2°C).
Data Analysis
Students unpaired t test (Figure 2C) and one-way ANOVA (Figure 2D) were used. P<0.05 was judged statistically significant.
|
| Results |
|---|
|
|
|---|
Functional Assay
The electrophysiological properties of the mutant Kir2.1 subunit were assayed by comparing oocytes injected with WT or mutant cRNA (10 ng/oocyte; Figure 2). The injection of WT cRNA induced K+ currents with strong inward rectification.8,9 The homomeric T192A mutant did not manifest measurable K+ currents. The coinjection of WT and mutant cRNA (5 ng of each per oocyte) resulted in a current approximately half of that induced by WT cRNA alone (10 ng/oocyte). The inward rectifying property remained unchanged, as indicated by the current-voltage relationships. Experiments using identical protocols were performed in multiple oocytes; pooled data are summarized in Figure 2C. Increases in the amount of T192A cRNA (0, 5, and 15 ng) resulted in a slight dose-dependent suppression of expressed current (WT cRNA, 5 ng/oocyte), which was statistically significant by one-way ANOVA (Figure 2D).
| Discussion |
|---|
|
|
|---|
As expected, homomeric T192A channels were completely nonfunctional. In the study by Plaster et al,6 D71V and R218W mutant subunits also failed to form functional homomeric channels. The coexpression of WT and D71V subunits induced an inwardly rectifying K+ current with severely reduced amplitude, demonstrating that D71V has a strong dominant-negative effect. The coexpression of R218W and WT also induced a significant K+ current reduction, whereas the coexpression of T192A and WT produced slight suppression of the Kir2.1 current, suggesting that it has only a minimal dominant-negative effect.
This observation can be explained by assuming that even a tetrameric combination of only one WT and 3 T192A subunits forms a functional channel. Only one intact PIP2 binding site may suffice for channel function. Alternatively, T192A may not be able to assemble with WT subunits; M2 and subsequent cytoplasmic regions including T192 are involved in Kir2.1 multimerization.14
Our patients did not manifest the dysmorphic features characteristic of Andersens syndrome. This suggests that that the functional modulation induced by T192A may be different from that induced by D71V or R218W.6
| Acknowledgments |
|---|
Received February 27, 2002; revision received April 15, 2002; accepted April 15, 2002.
| References |
|---|
|
|
|---|
2.
Lisak RP, Lebeau J, Tucker SH, et al. Hyperkalemic periodic paralysis with cardiac arrhythmia. Neurology. 1972; 22: 810815.
3. Levitt LP, Rose LI, Dawson DM. Hypokalemic periodic paralysis with arrhythmia. N Engl J Med. 1972; 286: 253234.
4. Sansone V, Griggs RC, Meola G, et al. Andersens syndrome: a distinct periodic paralysis. Ann Neurol. 1997; 42: 305312.[CrossRef][Medline] [Order article via Infotrieve]
5. Canun S, Pérez N, Beirana LG. Andersen syndrome autosomal dominant in three generations. Am J Med Genet. 1999; 85: 147156.[CrossRef][Medline] [Order article via Infotrieve]
6. Plaster N, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersens syndrome. Cell. 2001; 105: 511519.[CrossRef][Medline] [Order article via Infotrieve]
7. Andersen DE, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies: a new syndrome? Acta Paediat Scand. 1971; 60: 559564.[Medline] [Order article via Infotrieve]
8. Kubo Y, Baldwin TJ, Jan YN, et al. Primary structure and functional expression of a mouse inward rectifier potassium channel. Nature. 1993; 362: 127133.[CrossRef][Medline] [Order article via Infotrieve]
9. Raab-Graham KF, Radeke CM, Vandenberg CA. Molecular cloning and expression of a human heart inward rectifier potassium channel. Neurol Rep. 1994; 5: 25012505.
10.
Kunkel LM, Smith KD, Boyer SH, et al. Analysis of human Y-chromosome specific reiterated DNA in chromosome variants. Proc Natl Acad Sci U S A. 1977; 74: 12451249.
11. Yoshida H, Horie M, Otani H, et al. Characterization of a novel missense mutation in the pore of HERG in a patient with long QT syndrome. J Cardiovasc Electrophysiol. 1999; 10: 12621270.[Medline] [Order article via Infotrieve]
12.
Kubo Y, Murata Y. Control of rectification and permeation by two distinct sites after the second transmembrane region in Kir2.1 K+ channel. J Physiol. 2001; 531: 645660.
13. Soom M, Schönherr R, Kubo Y, et al. Multiple PIP2 binding sites in Kir2.1 inwardly rectifying potassium channels. FEBS Lett. 2001; 490: 4953.[CrossRef][Medline] [Order article via Infotrieve]
14. Tinker A, Jan YN, Jan LY. Regions responsible for the assembly of inwardly rectifying potassium channels. Cell. 1996; 87: 857868.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
N. Decher, V. Renigunta, M. Zuzarte, M. Soom, S. H. Heinemann, K. W. Timothy, M. T. Keating, J. Daut, M. C. Sanguinetti, and I. Splawski Impaired interaction between the slide helix and the C-terminus of Kir2.1: A novel mechanism of Andersen syndrome Cardiovasc Res, September 1, 2007; 75(4): 748 - 757. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Morita, D. P. Zipes, S. T. Morita, and J. Wu Mechanism of U wave and polymorphic ventricular tachycardia in a canine tissue model of Andersen-Tawil syndrome Cardiovasc Res, August 1, 2007; 75(3): 510 - 518. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bendahhou, E. Fournier, S. Gallet, D. Menard, M.-M. Larroque, and J. Barhanin Corticosteroid-exacerbated symptoms in an Andersen's syndrome kindred Hum. Mol. Genet., April 15, 2007; 16(8): 900 - 906. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Sung, S.-N. Wu, J.-S. Wu, H.-D. Chang, and C.-H. Luo Electrophysiological mechanisms of ventricular arrhythmias in relation to Andersen-Tawil syndrome under conditions of reduced IK1: a simulation study Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2597 - H2605. [Abstract] [Full Text] [PDF] |
||||
![]() |
C-W Lu, J-H Lin, Y S Rajawat, H Jerng, T G Rami, X Sanchez, G DeFreitas, B Carabello, F DeMayo, D L Kearney, et al. Functional and clinical characterization of a mutation in KCNJ2 associated with Andersen-Tawil syndrome J. Med. Genet., August 1, 2006; 43(8): 653 - 659. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Venance, S. C. Cannon, D. Fialho, B. Fontaine, M. G. Hanna, L. J. Ptacek, M. Tristani-Firouzi, R. Tawil, R. C. Griggs, and the CINCH investigators The primary periodic paralyses: diagnosis, pathogenesis and treatment Brain, January 1, 2006; 129(1): 8 - 17. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. P. Davies, P. Imbrici, D. Fialho, C. Herd, L. G. Bilsland, A. Weber, R. Mueller, D. Hilton-Jones, J. Ealing, B. R. Boothman, et al. Andersen-Tawil syndrome: New potassium channel mutations and possible phenotypic variation Neurology, October 11, 2005; 65(7): 1083 - 1089. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Nerbonne and R. S. Kass Molecular Physiology of Cardiac Repolarization Physiol Rev, October 1, 2005; 85(4): 1205 - 1253. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bendahhou, E. Fournier, D. Sternberg, G. Bassez, A. Furby, C. Sereni, M. R Donaldson, M.-M. Larroque, B. Fontaine, and J. Barhanin In vivo and in vitro functional characterization of Andersen's syndrome mutations J. Physiol., June 15, 2005; 565(3): 731 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang, D. W. Benson, M. Tristani-Firouzi, L. J. Ptacek, R. Tawil, P. J. Schwartz, A. L. George, M. Horie, G. Andelfinger, G. L. Snow, et al. Electrocardiographic Features in Andersen-Tawil Syndrome Patients With KCNJ2 Mutations: Characteristic T-U-Wave Patterns Predict the KCNJ2 Genotype Circulation, May 31, 2005; 111(21): 2720 - 2726. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Beery The Genetics of Cardiac Arrhythmias Biol Res Nurs, April 1, 2005; 6(4): 249 - 261. [Abstract] [PDF] |
||||
![]() |
P. S. Lange, F. Er, N. Gassanov, and U. C. Hoppe Andersen mutations of KCNJ2 suppress the native inward rectifier current IK1 in a dominant-negative fashion Cardiovasc Res, August 1, 2003; 59(2): 321 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Donaldson, J. L. Jensen, M. Tristani-Firouzi, R. Tawil, S. Bendahhou, W. A. Suarez, A. M. Cobo, J. J. Poza, E. Behr, J. Wagstaff, et al. PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome Neurology, June 10, 2003; 60(11): 1811 - 1816. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |